Faculty Bibliography

A combination of an experimental anti-AIDS virus drug and two licensed ones appears to be the most powerful AIDS therapy ever tested on infected patients, a researcher from the experimental drug's developer said at a scientific meeting yesterday. The three-drug combination reduced the amount of HIV, the AIDS virus, by 99 percent to levels that could not be detected by standard laboratory tests in 24 of 26 patients. The effect has lasted for nearly six months in one study, said Dr. Emilio Emini, a researcher at Merck, which developed the experimental drug. The two marketed drugs are AZT and 3TC, which the Glaxo-Wellcome company makes as Retrovir and Epivir. The experimental drug is Merck's indinavir, a member of a new class of anti-AIDS drugs known as protease inhibitors. This week Merck & Co. is asking the Food and Drug Administration for approval to market the drug as Crixivan. Merck officials said they did not know how much the drug would cost

A combination of an experimental anti-AIDS virus drug and two licensed ones appears to be the most powerful AIDS therapy ever tested on infected patients, a researcher from the experimental drug's developer said at a scientific meeting here Monday. The three-drug combination reduced the amount of HIV, the AIDS virus, by 99 per cent to levels that could not be detected by standard laboratory tests in 24 of 26 patients. The effect has lasted for nearly six months in one study, said Dr. Emilio Emini, a researcher at Merck, which developed the experimental drug

A combination of an experimental anti-AIDS virus drug and two licensed ones appears to be the most powerful AIDS therapy ever tested on infected patients, a researcher from the experimental drug's developer said at a scientific meeting here Monday. The three-drug combination reduced the amount of HIV, the AIDS virus, by 99 percent to levels that could not be detected by standard laboratory tests in 24 of 26 patients. Theeffect has lasted for nearly six months in one study, said Dr. Emilio Emini a researcher at Merck, which developed the experimental drug. The two marketed drugs are AZT and 3TC, which the Glaxo-Wellcome company makes as Retrovir and Epivir. The experimental drug is Merck's indinavir, a member of a new class of anti-AIDS drugs known as protease inhibitors. This week Merck & Co. is asking the Food and Drug Administration for approval to market the drug as Crixivan. Merck officials said they didn't know how much the drug would cost

The drug is the short-acting form of nifedipine, a member of a class known as calcium channel blockers. The drug is marketed as Procardia by Pfizer and as Adalat by Bayer. Doctors in the United States wrote more than 2 million prescriptions for short-acting nifedipine in 1994. Dr. Robert Temple, a top official of the FDA, said after the meeting in Bethesda, Md., that the federal agency was already working on changing the drug's label, in part because federal health officials warned last August that the short-acting drug should be used ''with great caution, if at all.'' Some studies have suggested that the drug may increase the risk of death from heart disease

An advisory committee to the FDA recommended on Jan 25, 1996 that the agency take steps to discourage doctors from prescribing a drug used to reduce high blood pressure and relieve the pain of angina. The drug is the short-acting form of nifedipine, a member of a class known as calcium channel blockers. The drug is marketed as Procardia by Pfizer Inc and as Adalat by the Bayer Co. Some studies have suggested the the drug may increase the risk of death from heart disease

An advisory committee to the Food and Drug Administration recommended Thursday night that the agency take steps to discourage doctors from prescribing a drug used to reduce high blood pressure and relieve the pains of angina. The drug is the short-acting form of nifedipine, a member of a class known as calcium channel blockers. The drug is marketed as Procardia by Pfizer Inc. and as Adalat by Bayer Co. Doctors in the United States wrote more than 2 million prescriptions for short-acting nifedipine in 1994

After several stays of execution, the smallpox virus, one of the biggest killers in history, is back on Death Row. The governing board of the World Health Organization recommended on Wednesday in Geneva, Switzerland, that the last two remaining stocks of the smallpox virus, in Russia and the United States, be destroyed by June 30, 1999. Wednesday's action was the most important step to date in the longstanding plans of WHO, an agency of the United Nations, to destroy the virus. Destruction of the virus stocks, the last vestiges of the infectious agent that has killed, scarred and blinded countless millions of people, would be the first deliberate extinction of a species

An advisory committee to the Food and Drug Administration recommended Thursday night that the agency take steps to discourage doctors from prescribing a drug used to reduce high blood pressure and relieve the pains of angina. The drug is the short-acting form of nifedipine, a member of a class known as calcium channel blockers. The drug is marketed as Procardia by Pfizer Inc. and as Adalat by Bayer Co. Doctors in the United States wrote more than 2 million prescriptions for short-acting nifedipine in 1994

The governing board of WHO recommended on Jan 24, 1996 in Geneva that what are believed to be the last two remaining stocks of the smallpox virus, in Russia and the US, be destroyed by Jun 30, 1999. Final action requires a vote of the full membership of the health organization, and approval is expected. Destruction of the stocks, the last vestiges of the infectious agent that is one of the biggest killers in history, could be the first deliberate extinction of a species

After several stays of execution, the smallpox virus, one of the biggest killers in history, is back on death row. The governing board of the World Health Organization recommended yesterday in Geneva that the last two remaining stocks of the smallpox virus, in Russia and the United States, be destroyed by June 30, 1999. Final action requires a vote of WHO's full membership, and approval is expected. Yesterday's action was the most important step to date in the U.N. agency's longstanding plans to destroy the virus. Destruction of the virus stocks, the last vestiges of the infectious agent that has killed, scarred and blinded countless millions of people, would be the first deliberate extinction of a species